Pharsight

Defencath patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541393 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
Nov, 2024

(5 months from now)

US9339036 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
Nov, 2024

(5 months from now)

US7696182 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
May, 2025

(11 months from now)

US11738120 CORMEDIX Synthesis of taurolidine, purity profiles and polymorphs
Apr, 2042

(17 years from now)

Defencath is owned by Cormedix.

Defencath contains Heparin Sodium; Taurolidine.

Defencath has a total of 4 drug patents out of which 0 drug patents have expired.

Defencath was authorised for market use on 15 November, 2023.

Defencath is available in solution;n/a dosage forms.

Defencath can be used as a catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter.

Drug patent challenges can be filed against Defencath from 15 November, 2032.

The generics of Defencath are possible to be released after 15 April, 2042.

Drug Exclusivity Drug Exclusivity Expiration
Generating Antibiotic Incentives Now(GAIN) Nov 15, 2033
New Chemical Entity Exclusivity(NCE) Nov 15, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient

NCE-1 date: 15 November, 2032

Market Authorisation Date: 15 November, 2023

Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter

Dosage: SOLUTION;N/A

More Information on Dosage

DEFENCATH family patents

Family Patents